Inhaled Therapies for Pulmonary Hypertension

Area of Science:

• Pulmonary Medicine
• Pharmacology
• Respiratory Therapy

Background:

• The inhaled route provides direct drug delivery to the lungs for pulmonary hypertension treatment.
• This enhances pulmonary specificity, reduces systemic side effects, and improves gas exchange.
• Inhaled agents can achieve higher local concentrations at lower doses, potentially reducing costs.

Purpose of the Study:

• To review current inhaled therapies for pulmonary hypertension.
• To discuss the advantages and limitations of existing inhaled agents.
• To explore the future potential of inhaled small molecules for pulmonary arterial hypertension (PAH).

Main Methods:

• Review of current literature on inhaled therapies for pulmonary hypertension.
• Analysis of approved and investigational inhaled agents.
• Discussion of the benefits and drawbacks of different inhaled delivery methods.

Main Results:

• Prostacyclins like aerosolized iloprost and treprostinil are FDA-cleared for PAH but require frequent administration and can cause airway symptoms.
• Inhaled nitric oxide (INO) is approved for newborns and used off-label for vasoreactivity testing and acute heart failure.
• Current inhaled prostacyclins have limitations in high-dose delivery compared to infused routes.

Conclusions:

• The inhaled route offers significant advantages for pulmonary hypertension treatment.
• Existing inhaled prostacyclins have limitations, necessitating further research.
• Future development is likely to focus on novel inhaled small molecules for PAH, leveraging the lung-targeting benefits.